132 related articles for article (PubMed ID: 38763723)
41. Zein-Paclitaxel Prodrug Nanoparticles for Redox-Triggered Drug Delivery and Enhanced Therapeutic Efficiency.
Hou H; Zhang D; Lin J; Zhang Y; Li C; Wang Z; Ren J; Yao M; Wong KH; Wang Y
J Agric Food Chem; 2018 Nov; 66(44):11812-11822. PubMed ID: 30339011
[TBL] [Abstract][Full Text] [Related]
42. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
[TBL] [Abstract][Full Text] [Related]
43. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
44. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
45. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
[TBL] [Abstract][Full Text] [Related]
46. Dual-responsive nanoparticles based on chitosan for enhanced breast cancer therapy.
Zhang X; Niu S; Williams GR; Wu J; Chen X; Zheng H; Zhu LM
Carbohydr Polym; 2019 Oct; 221():84-93. PubMed ID: 31227170
[TBL] [Abstract][Full Text] [Related]
47. Dual stimuli-responsive ursolic acid-embedded nanophytoliposome for targeted antitumor therapy.
Poudel K; Gautam M; Maharjan S; Jeong JH; Choi HG; Khan GM; Yong CS; Kim JO
Int J Pharm; 2020 May; 582():119330. PubMed ID: 32298743
[TBL] [Abstract][Full Text] [Related]
48. A Photopolymerized Semi-Interpenetrating Polymer Networks-Based Hydrogel Incorporated with Nanoparticle for Local Chemotherapy of Tumors.
Wang Y; Li Q; Zhou JE; Tan J; Li M; Xu N; Qu F; Chen J; Li J; Wang J; Liang Z; Yu L; Wang Y; Yan Z
Pharm Res; 2021 Apr; 38(4):669-680. PubMed ID: 33796952
[TBL] [Abstract][Full Text] [Related]
49. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
Xu Y; Liu D; Hu J; Ding P; Chen M
Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
[TBL] [Abstract][Full Text] [Related]
50. Redox-Responsive and Dual-Targeting Hyaluronic Acid-Methotrexate Prodrug Self-Assembling Nanoparticles for Enhancing Intracellular Drug Self-Delivery.
Zhang Y; Li Y; Tian H; Zhu Q; Wang F; Fan Z; Zhou S; Wang X; Xie L; Hou Z
Mol Pharm; 2019 Jul; 16(7):3133-3144. PubMed ID: 31198046
[TBL] [Abstract][Full Text] [Related]
51. Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel.
Li J; Yin T; Wang L; Yin L; Zhou J; Huo M
Int J Pharm; 2015 Apr; 483(1-2):38-48. PubMed ID: 25655715
[TBL] [Abstract][Full Text] [Related]
52. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
[TBL] [Abstract][Full Text] [Related]
53. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery.
Chu B; Qu Y; Huang Y; Zhang L; Chen X; Long C; He Y; Ou C; Qian Z
Int J Pharm; 2016 Mar; 500(1-2):345-59. PubMed ID: 26794876
[TBL] [Abstract][Full Text] [Related]
54. Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy.
He X; Zhang J; Li C; Zhang Y; Lu Y; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Guo Q; Sun T; Cheng J; Jiang C
Theranostics; 2018; 8(18):4884-4897. PubMed ID: 30429875
[TBL] [Abstract][Full Text] [Related]
55. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
56. tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.
Ma Y; Li R; Dong Y; You C; Huang S; Li X; Wang F; Zhang Y
Int J Nanomedicine; 2021; 16():789-802. PubMed ID: 33568906
[TBL] [Abstract][Full Text] [Related]
57. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
58. Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy.
Luo K; Yin S; Zhang R; Yu H; Wang G; Li J
Int J Pharm; 2020 Nov; 589():119870. PubMed ID: 32919005
[TBL] [Abstract][Full Text] [Related]
59. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
60. Enhanced cytotoxicity of a redox-sensitive hyaluronic acid-based nanomedicine toward different oncocytes via various internalization mechanisms.
Du Y; Wang S; Zhang T; He D; Tu J; Shen Y
Drug Deliv; 2020 Dec; 27(1):128-136. PubMed ID: 31894722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
